Unlock Native & Engineered Exosomes with Improved Targeting, Optimize Analytics & Achieve Large-Scale Manufacturing for Effective Translation into the Clinic & Towards Commercialization
Uniting Key Biopharma and Academics Dedicated to Successfully Developing
Since the hugely successful 2022 Exosome Based Therapeutic Development Summit, it’s clear that the space is rapidly evolving and is now entering a truly transformational time. As more and more investment pours into the space, the potential applications for exosome therapeutics and their delivery power continue to grow and the huge possibilities are only just starting to unfold.
With key collaborations including $500M IPO for Ilias and HK.inno to co-develop Exosomes and Eli Lilly securing a $1.1B deal with Evox Therapeutics to utilize their IN-NO-vative exosome-based RNA drugs to target the brain, developments like these underscore the potential for exosome-based therapeutics to revolutionize the way we treat diseases.
The 5th event in the series returns with a refreshed program, with data-driven insights from those pioneering the field including Capricor Therapeutics, Aegle Therapeutics, Rion and more who are going to be sharing key learnings alongside 30+ other Global Leaders to enable the successful clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.
This is the most comprehensive, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes, achieve GMP of EVs for clinical applications, and successfully deliver payloads to the target tissue with reduced toxicity. To support the ongoing challenge of exosome characterization, this year features a brand-new focus day on analytical development, diving into characterization assays, purification, and potency assays to enable robust translation into the clinic.
What to expect:
3 days of carefully curated content
2 tracks of content covering preclinical & discovery aspects alongside a track dedicated to clinical development and manufacturing
125+ attendees from all stages of the R&D process
30 key speakers who are pioneering in the exosome field
1 new pre-conference focus day diving into analytical development and characterization
Join 115+ of your peers from a growing landscape covering all stages of R&D, including Discovery, Preclinical, Clinical, Manufacturing, and Analytics. Don’t miss out on joining the industry leaders to benchmark your progress, hear data-driven case studies, and take advantage of the networking opportunities throughout the 3 days to fast-track exosome therapeutics and delivery through to commercialization.
Download the Full Event Guide for more information on:
- 30+ Expert Speaker Faculty
- Interactive pre-conference workshop day
- Full access to the 3-day conference agenda
- & more
Hear from our 2023 speakers
Alex Tendler, Chief Technology Officer, ExoProTher Medical
“Very interesting and valuable to get the perspective of other teams working with EVs in different therapeutic and diagnostic fields. I believe that such knowledge sharing will make a positive impact on all participants. Another important avenue is a possibility of a fruitful connection between developers and service providers in the field”
Katie Gillian, Head of Research & Development, OmniSpirant
“I think it is incredibly valuable to take part in this
meeting to increase the knowledge and potential of the clinical application of EVs. The field is growing rapidly and the translation from bench to bedside needs to be performed to the highest standard”